Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrell
Read the official notice at FDA (drug) →
Get alerts for Breckenridge Pharmaceutical
The text below is copied from the official FDA (drug) record. If anything differs, the official notice is correct.
- Company / brand
- Breckenridge Pharmaceutical, Inc.
- Product
- Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10.
- Reason / hazard
- CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
- Classification
- Class II
- Status
- Ongoing
- Distribution / sold at
- Nationwide within the United States
- Recall initiated
- 2025-11-24
- Code info
- Lot #: 240947C, 240962C, Exp. Date 04/2027
- Product quantity
- 3397 bottles
- Voluntary mandated
- Voluntary: Firm initiated
- City
- Berkeley Heights
- State
- NJ
- Country
- United States
- Event id
- 98034
Free daily digest + "My products" watchlist